AR110088A1 - Inhibidores de magl - Google Patents

Inhibidores de magl

Info

Publication number
AR110088A1
AR110088A1 ARP170103183A ARP170103183A AR110088A1 AR 110088 A1 AR110088 A1 AR 110088A1 AR P170103183 A ARP170103183 A AR P170103183A AR P170103183 A ARP170103183 A AR P170103183A AR 110088 A1 AR110088 A1 AR 110088A1
Authority
AR
Argentina
Prior art keywords
compounds
compositions
6haloalkyl
6alkyl
co2h
Prior art date
Application number
ARP170103183A
Other languages
English (en)
Inventor
Donald L Hertzog
Nicole S White
Daniel J Buzard
Cheryl A Grice
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of AR110088A1 publication Critical patent/AR110088A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Carbamatos de piperazina y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y las composiciones de la presente son útiles como moduladores de MAGL. Además, los compuestos y las composiciones son de utilidad para el tratamiento de dolor. Reivindicación 1: Un compuesto, caracterizado porque presenta la estructura de la fórmula (1); en donde: R¹ es -N(R³)(R⁵) o -NH(R⁴); cada R² se selecciona de manera independiente entre halógeno, C₁₋₆alquilo, -CN, C₁₋₆haloalquilo y -OR⁶; R³ es -CH₂CO₂H, -CH₂CH₂CO₂H o -CH(CH₃)CO₂H; R⁴ es -(CH₂)ₘ-CO₂H; R⁵ es H o C₁₋₃alquilo; cada R⁶ se selecciona de manera independiente entre H, C₁₋₆alquilo y C₁₋₆haloalquilo; n es 0, 1, 2, 3 ó 4; y m es 3; o una sal o un solvato farmacéuticamente aceptable del mismo.
ARP170103183A 2016-11-16 2017-11-15 Inhibidores de magl AR110088A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423095P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
AR110088A1 true AR110088A1 (es) 2019-02-20

Family

ID=62107273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103183A AR110088A1 (es) 2016-11-16 2017-11-15 Inhibidores de magl

Country Status (27)

Country Link
US (1) US9981930B1 (es)
EP (1) EP3541822B1 (es)
JP (1) JP6987859B2 (es)
KR (1) KR20190077087A (es)
CN (1) CN110248947B (es)
AR (1) AR110088A1 (es)
AU (1) AU2017361250A1 (es)
BR (1) BR112019009991A2 (es)
CA (1) CA3043612A1 (es)
CL (1) CL2019001335A1 (es)
CO (1) CO2019005038A2 (es)
CR (1) CR20190243A (es)
DO (1) DOP2019000121A (es)
EA (1) EA201991074A1 (es)
EC (1) ECSP19035377A (es)
ES (1) ES2908632T3 (es)
IL (1) IL266550A (es)
JO (1) JOP20190105A1 (es)
MA (1) MA46860A (es)
MX (1) MX2019005771A (es)
NI (1) NI201900050A (es)
PE (1) PE20191146A1 (es)
PH (1) PH12019501102A1 (es)
RU (1) RU2019116514A (es)
TN (1) TN2019000150A1 (es)
TW (1) TW201831458A (es)
WO (1) WO2018093946A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3698782B1 (en) 2012-01-06 2024-05-15 H. Lundbeck A/S Carbamate compounds for use in therapy
KR20180004263A (ko) 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
SI3541807T1 (sl) 2016-11-16 2022-01-31 H. Lundbeck A/S Kristalinična oblika zaviralca MAGL
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
MX2020004839A (es) * 2017-11-02 2020-10-16 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
US10570106B2 (en) 2018-05-15 2020-02-25 Lundbeck La Jolla Research Center, Inc. MAGL inhibitors
JP2023523219A (ja) * 2020-04-21 2023-06-02 ハー・ルンドベック・アクチエゼルスカベット モノアシルグリセロールリパーゼ阻害剤の合成
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (es) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (en) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Plant growth inhibitor
EP0619804B1 (en) 1991-11-27 1996-05-22 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
WO1997018196A1 (en) 1995-11-15 1997-05-22 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
CA2386540A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
KR20070026382A (ko) 2004-02-18 2007-03-08 아스트라제네카 아베 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
AR048528A1 (es) * 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
US7786113B2 (en) 2004-12-23 2010-08-31 Hoffman-La Roche Inc. Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
ME02222B (me) 2004-12-30 2016-02-20 Janssen Pharmaceutica Nv Amid derivati piperidin-i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za liječenje tjeskobe, boli i drugih stanja
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
JP2009527459A (ja) 2006-02-23 2009-07-30 武田薬品工業株式会社 縮合窒素含有複素環化合物
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｈｄｌ上昇剤
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US20110118286A1 (en) 2008-07-16 2011-05-19 Santhosh Francis Neelamkavil Bicyclic heterocycle derivatives and their use as gpcr modulators
US8772318B2 (en) 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
JP2012521425A (ja) 2009-03-23 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
TWI506011B (zh) 2009-11-03 2015-11-01 Bayer Materialscience Ag 在光聚合物調配物中作為添加劑之氟胺基甲酸酯
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP3698782B1 (en) 2012-01-06 2024-05-15 H. Lundbeck A/S Carbamate compounds for use in therapy
CN115536635A (zh) 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
KR20180004263A (ko) * 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
CN110248947B (zh) 2022-04-01
US20180134675A1 (en) 2018-05-17
BR112019009991A2 (pt) 2019-08-27
TN2019000150A1 (en) 2020-10-05
EP3541822A4 (en) 2020-04-29
TW201831458A (zh) 2018-09-01
ECSP19035377A (es) 2019-05-31
US9981930B1 (en) 2018-05-29
JP6987859B2 (ja) 2022-01-05
KR20190077087A (ko) 2019-07-02
JP2020502047A (ja) 2020-01-23
NI201900050A (es) 2019-10-30
CA3043612A1 (en) 2018-05-24
CN110248947A (zh) 2019-09-17
EP3541822A1 (en) 2019-09-25
EA201991074A1 (ru) 2019-12-30
JOP20190105A1 (ar) 2019-05-09
EP3541822B1 (en) 2022-01-19
MA46860A (fr) 2019-09-25
MX2019005771A (es) 2019-12-05
DOP2019000121A (es) 2019-09-30
ES2908632T3 (es) 2022-05-03
RU2019116514A (ru) 2020-12-17
WO2018093946A1 (en) 2018-05-24
CO2019005038A2 (es) 2019-05-31
CL2019001335A1 (es) 2019-10-04
PE20191146A1 (es) 2019-09-02
CR20190243A (es) 2019-06-26
IL266550A (en) 2019-07-31
PH12019501102A1 (en) 2019-08-19
AU2017361250A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
AR110088A1 (es) Inhibidores de magl
AR119761A2 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20170227A (es) Cromanos sutituidos y métodos para su uso
AR101456A1 (es) Inhibidores de cinasa c de proteína y métodos para usarse
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR104415A1 (es) Compuestos antiestrogénicos derivados de cromeno
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
CU20170007A7 (es) Compuestos de imidazopiridazina
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
AR101395A1 (es) Derivados de indolizina y su uso en enfermedades neurodegenerativas
AR118729A1 (es) Inhibidor selectivo de la jak1 quinasa
AR108010A1 (es) Derivados de indolina y su uso como inhibidores de ews-fli1
AR096148A1 (es) Terapia combinada para el tratamiento del cáncer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
AR106185A1 (es) Compuestos macrocíclicos de sulfondiimina
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR101290A1 (es) Inhibidores de aldosterona sintasa
AR111271A1 (es) Inhibidores dobles de magl y faah

Legal Events

Date Code Title Description
FB Suspension of granting procedure